A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
Page 1 of 1
A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
Jon Moulton Mon Apr 27, 2015 12:18 pm
Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics. 2015;5(8):834-46. doi:10.7150/thno.12040
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA -
Similar topics» A Clearance Step will become Increasingly Crucial for Pretargeted Tumor Therapy when Tumor Accumulation is Improved
» Five-Step Process for Screening Antisense Compounds for Efficacy: Gene Target IL-12Rb2
» Morphogenetic defects underlie Superior Coloboma, a newly identified closure disorder of the dorsal eye
» BMP, Wnt and FGF signals are integrated through evolutionarily conserved enhancers to achieve robust expression of Pax3 and Zic genes at the zebrafish neural plate border
» Inhibition of KSHV-associated lymphoma engraftment in SCID mouse by morpholino oligomers
» Five-Step Process for Screening Antisense Compounds for Efficacy: Gene Target IL-12Rb2
» Morphogenetic defects underlie Superior Coloboma, a newly identified closure disorder of the dorsal eye
» BMP, Wnt and FGF signals are integrated through evolutionarily conserved enhancers to achieve robust expression of Pax3 and Zic genes at the zebrafish neural plate border
» Inhibition of KSHV-associated lymphoma engraftment in SCID mouse by morpholino oligomers
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum|
|
|